Protagonist (PTGX) news

Protagonist Therapeutics, Inc.: Leerink partners assumes coverage with outperform rating; target price $190

Leerink Partners has initiated coverage of Protagonist Therapeutics, Inc. with an "outperform" rating and a target price of $190 per share. The decision reflects the firm’s assessment of the company’s therapeutic pipeline and its potential for long-term growth. While specific details of the firm’s…

Axis Capital raises PSB bid to EUR 3.20/share vs Bawag

Axis Capital Holdings Limited (AXS) has increased its bid for Permanent TSB Group Holdings plc (PTSB) to €3.20 per share, valuing the Irish retail bank at approximately €1.62 billion. The revised offer represents a significant step in the ongoing acquisition process, which has been recommended by…

Protagonist Therapeutics, Inc.: Citigroup raises target price to $182 from $175

Citigroup has raised its price target for Protagonist Therapeutics, Inc. (NASDAQ: PTGX) to $182 from $175, maintaining its “buy” rating for the stock. This adjustment implies potential upside of approximately 24.6% from the stock’s closing price as of August 29, 2026. The move follows upgrades from…

Protagonist Therapeutics, Inc.: H.C. Wainwright raises target price to $170 from $167

Jefferies lifts its Protagonist Therapeutics price target to $171, up from $169.

Jefferies has raised its price target for Protagonist Therapeutics (PTGX) to $171, an increase from the previous $169, reflecting a positive outlook on the company’s recent developments and pipeline progress. The adjustment comes amid growing analyst optimism, with 14 analysts currently rating the…